These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32059669)

  • 1. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
    Wang Q; Luo M; Xiang B; Chen S; Ji Y
    Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
    Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
    Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
    El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
    Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
    Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
    Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
    Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S
    Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
    Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
    Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
    Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM).
    Faehling M; Wienhausen-Wilke V; Fallscheer S; Trinajstic-Schulz B; Weber J; Leschke M
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):259-64. PubMed ID: 26422572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
    Gao N; Zhang T; Ji J; Xu KF; Tian X
    Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
    Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
    Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of lymphangioleiomyomatosis.
    Taillé C; Borie R; Crestani B
    Curr Opin Pulm Med; 2011 Sep; 17(5):374-8. PubMed ID: 21760507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
    J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
    Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
    Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
    Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
    El-Chemaly S; Henske EP
    Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
    Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
    Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.